Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

David Albers to Cholangiocarcinoma

This is a "connection" page, showing publications David Albers has written about Cholangiocarcinoma.

 
Connection Strength
 
 
 
0.182
 
  1. Virchow I, Treckmann JW, Prasnikar N, Linden G, Markus P, Schumacher B, Albers D, Herold T, Ting S, Schmidt H, Radunz S, Wiesweg M, Siveke J, Schuler M, Kasper S. A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO). Oncol Res Treat. 2023; 46(3):89-99.
    View in: PubMed
    Score: 0.182
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)